Evidence map›Paper›PMID 38066255›Full record

SynthesisJournal of neuro-oncology2023

Ganciclovir as a potential treatment for glioma: a systematic review and meta-analysis.

Chun-Tao Chang, Hsing-Hui Chen, Chun-Chao Chuang, Shao-Hsun Chang, Nai-Wan Hsiao

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Chun-Tao ChangDepartment of Biology, National Changhua University of Education, No. 1, Jinde Rd, Changhua City, Changhua County, 500207, Taiwan.
Hsing-Hui ChenDepartment of Industrial Education and Technology, National Changhua University of Education, No. 1, Jinde Rd, Changhua City, Changhua County, 500207, Taiwan.
Chun-Chao ChuangDepartment of Medical Imaging and Radiological Sciences, Chung Shan Medical University, No. 110, Sec. 1, Jianguo N. Rd, South Dist., Taichung City, 402306, Taiwan.
Shao-Hsun ChangDepartment of Industrial Education and Technology, National Changhua University of Education, No. 1, Jinde Rd, Changhua City, Changhua County, 500207, Taiwan.
Nai-Wan HsiaoDepartment of Biology, National Changhua University of Education, No. 1, Jinde Rd, Changhua City, Changhua County, 500207, Taiwan. nady@cc.ncue.edu.tw.ORCID http://orcid.org/0000-0003-3473-1584
National Changhua University of Education · TWChung Shan Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioma is a challenging malignant tumor with a low survival rate and no effective treatment. Recently, ganciclovir, an antiviral drug, combined with gene therapy and its own antiviral ability, has been proposed as a potential treatment for glioma. However, there are differences in the results of various clinical trials. In this study, we conducted a systematic review and meta-analysis to evaluate the efficacy of ganciclovir in treating glioma.

methodsWe searched databases such as PubMed, EMBASE, and Cochrane Library before March 30, 2023. The search terms included glioma, ganciclovir, valganciclovir and treatment. Calculated 1, 2 and 4-year survival rate by risk difference (RD), and overall survival (OS) by odds ratio (OR).

resultsFive randomized controlled trials (RCTs) with a total of 606 high-grade glioma patients were included. The results showed that ganciclovir can improve 2-yeaer (RD = 0.179, 95% CI 0.012-0.346, P = 0.036) and 4-year survival rate (RD = 0.185, 95% CI 0.069-0.3, P = 0.002) and OS (OR 2.393, 95% CI 1.212-4.728, P = 0.012) compared with the control group.

conclusionsThis meta-analysis showed that ganciclovir significantly improved the prognosis of glioma patients. Therefore, we suggest that more cases of ganciclovir as a glioma treatment can be conducted, or a large clinical trial can be designed.

Indexed as

GanciclovirGliomaHumansPrognosisRandomized Controlled Trials as TopicGanciclovirDrug repurposingGanciclovirGlioblastomaGliomaValganciclovir

Identifiers

PMID38066255
OpenAlexW4389473797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.